AETHLON MEDICAL (AEMD) Company Report

Aethlon Medical is developing its Hemopurifier device, which removes cancerous extracellular vesicles, with a primary focus on oncology patients with solid tumors who are not responding to anti-PD-1 therapies like Keytruda or Opdivo.
The company has completed treatments for the second cohort of its safety and feasibility study in Australia, with an independent Data Safety Monitoring Board meeting scheduled for March to review safety and determine progression to the third cohort.
As of December 31st, Aethlon Medical reported a cash position of approximately $7 million and a monthly burn rate of about $500,000. This, combined with access to an additional $1.8 million via an at-the-market offering, is expected to fund the company through the current trial.
The Australian clinical trial benefits from a 43% tax rebate on expenditures, and the Hemopurifier holds Breakthrough Device designations from the FDA for both viral and oncology indications.

6 days ago

Transcript

Aethlon Medical Provides Update on Hemopurifier Clinical Trial Progress and Financial Position

AEMD

New Projects/Investments

Guidance Update

Aethlon Medical is conducting a 3-cohort safety, feasibility, and dose-finding study in Australia for its Hemopurifier in patients with solid tumors not responding to anti-PD-1 therapy.
The first two cohorts of the study have completed treatments, with the first cohort showing no dose-limiting toxicities or serious device-related adverse events.
A Data Safety Monitoring Board meeting is anticipated in March to review Cohort 2 safety and potentially approve progression to the third cohort, with data analysis from the University of Sydney expected in the June quarter.
As of December 31st, the company had approximately $7 million in cash, a monthly burn rate of $500,000, and access to an additional $1.8 million via an at-the-market offering, providing a runway through the current trial.
The company benefits from a 43% tax rebate on Australian clinical trial expenditures and holds Breakthrough Device designations from the FDA for both viruses and oncology.

6 days ago

Transcript

Aethlon Medical, Inc. Stockholders Approve Increase in Authorized Shares and Equity Incentive Plan Amendment

AEMD

Proxy Vote Outcomes

Executive Compensation

Aethlon Medical, Inc. stockholders approved an amendment to the Articles of Incorporation on February 19, 2026, to increase the total authorized shares of common stock from 6,000,000 shares to 100,000,000 shares.
Stockholders also approved an amendment to the 2020 Equity Incentive Plan on February 19, 2026, which increased the number of shares authorized for issuance under the plan by 100,000 shares.
Following this amendment, the aggregate number of shares that may be issued pursuant to awards under the 2020 Equity Incentive Plan is 142,052 shares.
Additionally, stockholders approved the issuance of up to 1,662,553 shares and 368,471 shares of Common Stock related to warrants, for the purpose of complying with Nasdaq Listing Rule 5635(d).

Feb 23, 2026, 9:15 PM

8-K

Aethlon Medical Reports Q3 2026 Financials and Oncology Trial Progress

AEMD

Earnings

New Projects/Investments

Aethlon Medical reported a cash balance of approximately $7 million as of December 31, 2025. For the three months ended December 31, 2025, consolidated operating expenses were $2.06 million, resulting in an operating loss of $2.06 million.
The company is progressing in its Australian oncology trial, having completed the first cohort and treated two participants in the second, with a third patient expected to receive treatment by the end of February. An independent Data Safety Monitoring Board (DSMB) will review cohort 2 safety data in late March to determine advancement to cohort 3.
Aethlon is evaluating the Hemopurifier's compatibility with Stavro's SLAMB system, which could simplify treatments and enable use in oncology and infusion centers, expanding future clinical and commercial flexibility.
Operating expenses for the nine-month period ended December 31, 2025, decreased by 27% to $5.36 million compared to the prior year, driven by ongoing cost management initiatives.

Feb 12, 2026, 9:30 PM

Transcript

Aethlon Medical Reports Q3 2026 Financials and Australian Oncology Trial Progress

AEMD

Earnings

New Projects/Investments

Aethlon Medical reported a cash balance of approximately $7 million as of December 31, 2025.
For the third fiscal quarter ended December 31, 2025, consolidated operating expenses were $2.06 million, leading to an operating loss of $2.06 million, while year-to-date operating expenses decreased by 27% to $5.36 million compared to the prior year.
Progress continues in the Australian oncology trial, with two participants completing two Hemopurifier treatments in Cohort 2, and a third patient expected to complete treatment by the end of February 2026; a Data Safety Monitoring Board meeting is targeted for late March 2026 to provide a recommendation on advancing to Cohort 3.
The company is advancing work on Hemopurifier compatibility with Stavro's SLAMB system to simplify blood treatment, potentially expanding its use to oncology units and infusion centers, and is expanding its extracellular vesicle (EV) research platform.

Feb 12, 2026, 9:30 PM

Transcript

Aethlon Medical Reports Q3 2026 Financials and Clinical Trial Progress

AEMD

Earnings

New Projects/Investments

Aethlon Medical ended Q3 fiscal 2026 (December 31, 2025) with a cash balance of approximately $7 million.
Consolidated operating expenses for Q3 fiscal 2026 were $2.06 million, resulting in an operating loss of $2.06 million for the quarter, though year-to-date operating expenses decreased 27% to $5.36 million compared to the prior year.
The company is advancing its Australian oncology trial, having completed the first cohort and treated two of three participants in the second cohort, with safety data for this cohort expected to be presented to a data safety monitoring board in late March.
Aethlon is exploring the Hemopurifier's compatibility with a simplified blood treatment system (SLAMB system), which could expand treatment accessibility to oncology units and infusion centers by reducing invasiveness and reliance on dialysis infrastructure.

Feb 12, 2026, 9:30 PM

Transcript

Aethlon Medical Reports Fiscal Q3 2026 Financial Results and Clinical Progress

AEMD

Earnings

New Projects/Investments

Aethlon Medical reported a cash balance of approximately $7.0 million as of December 31, 2025.
For the fiscal third quarter ended December 31, 2025, operating expenses increased by 13.6% to $2.06 million compared to $1.81 million in the prior year period, primarily due to higher payroll and related costs.
The company's net loss for the quarter was $2.02 million, resulting in a basic and diluted loss per share of $(2.45).
For the nine months ended December 31, 2025, consolidated operating expenses decreased by 26.9% to $5.36 million from $7.34 million in the same period in 2024, reflecting ongoing cost efficiencies.
Operationally, Cohort 2 of the Australian oncology trial is actively progressing, and the company continues to advance its preclinical extracellular vesicle research.

Feb 12, 2026, 9:15 PM

Press Release

Totaligent Executes Binding LOI for Aetherium Medical Acqui-hire

AEMD

M&A

New Projects/Investments

Hiring

Totaligent, Inc. (OTCID: TGNT) has executed a binding Letter of Intent (LOI) for the acqui-hire of Aetherium Medical's team, intellectual property, and assets.
Aetherium Medical specializes in providing infrastructure for biotechnology companies to connect with global patients for next-generation biologic therapies via ethical medical tourism channels.
The transaction involves no cash consideration at closing; instead, Totaligent will issue restricted preferred stock representing 10% of its outstanding equity to the Aetherium team upon closing.
The deal is targeted to close in approximately four weeks (around early March 2026), subject to satisfactory due diligence and execution of definitive agreements.

Feb 12, 2026, 2:00 PM

Press Release

Aethlon Medical Announces $3.3 Million Private Placement and Warrant Inducement

AEMD

Aethlon Medical, Inc. announced a private placement and warrant inducement expected to generate approximately $3.3 million in gross proceeds.
The private placement involves the purchase of 595,897 shares of common stock (or pre-funded warrants) and warrants to purchase up to an aggregate 1,042,820 shares of common stock, with a combined effective offering price of $4.03 per share.
The company also entered into a warrant inducement agreement, reducing the exercise price of outstanding March 2025 and September 2025 warrants to $4.03, leading to the exercise of 155,000 shares and 55,555 shares, respectively.
In consideration for the immediate exercise of these warrants, Aethlon Medical agreed to issue new unregistered warrants to purchase an aggregate of 368,471 shares.
The offering is expected to close on or about December 8, 2025.

Dec 5, 2025, 2:15 PM

Press Release

Aethlon Medical Reports Q2 2026 Financials and Advances Oncology Trial

AEMD

Earnings

New Projects/Investments

Aethlon Medical reported a cash balance of approximately $5.8 million as of September 30, 2025.
For the fiscal second quarter ended September 30, 2025, consolidated operating expenses decreased by $1.4 million, or 48%, to $1.5 million, resulting in an operating loss of $1.5 million.
The company successfully completed chemopurifier treatments for three participants in cohort one of its Australian oncology trial without device deficiencies or serious adverse events, leading to the recommendation to advance to cohort two on July 11, 2025.
Initial data from cohort one showed decreases in large extracellular vesicles (EVs), including those with PD-L1, and improvements in laboratory ratios associated with immunotherapy responses in some participants.
Aethlon is also advancing preclinical R&D, including presenting data on the chemopurifier's binding to Long COVID-related extracellular vesicles and signing a Material Transfer Agreement (MTA) to develop a simplified chemopurifier system.